Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?Wall Street's been pounding the table on Viking Therapeutics because VK2735 could become the next and best dual ...
GlobalData on MSN22h
Viking stock fluctuates amid manufacturing concerns with obesity pillViking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback